An advanced well-differentiated pancreatic neuroendocrine carcinoma (NET-G3) associated with von hippel-lindau disease

Masami Miki, Ken Kawabe, Hisato Igarashi, Tatsuro Abe, Yoshihiro Ohishi, Risa Hashimoto, Takashi Karashima, Ichiro Yamasaki, Keiji Inoue, Tetsuhide Ito, Yoshihiro Ogawa

研究成果: ジャーナルへの寄稿記事

抜粋

A 45-year old woman who underwent several surgeries for tumors associated with von Hippel-Lindau disease (VHL) was referred to our hospital due to a pancreatic tumor and liver tumors. She was diagnosed with pancreatic neuroendocrine tumor (NET) with a Ki67 index of 40% based on the examination of a biopsy specimen of the liver tumors. She was treated with everolimus for 6 months and sunitinib for 6 weeks as first-and second-line therapies. She survived for 13 months. At autopsy the diagnosis of pancreatic neuroendocrine tumor (NET)-G3 was confirmed. We herein report an aggressive clinical course of VHL-related NET G3. The further accumulation of cases is required to reach a consensus on treatment for this disease.

元の言語英語
ページ(範囲)2007-2011
ページ数5
ジャーナルInternal Medicine
57
発行部数14
DOI
出版物ステータス出版済み - 1 1 2018

    フィンガープリント

All Science Journal Classification (ASJC) codes

  • Internal Medicine

これを引用